Mallin W H, Elgazzar A H, Maxon H R
Department of Radiology, Eugene L. Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, OH 45267-0577.
Am J Otolaryngol. 1994 Nov-Dec;15(6):417-22. doi: 10.1016/0196-0709(94)90082-5.
The treatment of primary thyroid cancer requires protracted follow-up because of to the possibility of the development of recurrent metastases many years after the initial diagnosis. Often such follow-up involves imaging at regular intervals with diagnostic I-131 studies. However, not all thyroid cancer concentrates I-131. The purpose of this article is to review the efficacy of alternative diagnostic imaging modalities for follow-up of thyroid carcinomas that do not concentrate radioiodine.
These procedures include the use of nuclear medicine imaging with thallium-201 (TI-201), Tc-99m-sestamibi, Tc-99m pentavalent dimercaptosuccinic acid (DMSA), radiolabeled anti-carcinoembryonic antigen antibodies, and radioiodinated-131 meta-iodobenzyl guanidine, as well as computerized x-ray tomography, magnetic resonance imaging (MRI), and ultrasound (US).
Thallium-201, MRI, and pentavalent DMSA provide adequate sensitivity for follow-up of selected patients with suspected recurrent noniodine concentrating thyroid carcinoma.
由于原发性甲状腺癌在初次诊断多年后仍有可能发生复发性转移，因此其治疗需要长期随访。这种随访通常包括定期进行诊断性I-131检查成像。然而，并非所有甲状腺癌都能摄取I-131。本文旨在综述用于不摄取放射性碘的甲状腺癌随访的替代诊断成像方式的疗效。
这些检查方法包括使用核医学成像，如铊-201（TI-201）、锝-99m-甲氧基异丁基异腈、锝-99m五价二巯基丁二酸（DMSA）、放射性标记的抗癌胚抗原抗体以及放射性碘化-131间碘苄胍，同时还包括计算机断层扫描、磁共振成像（MRI）和超声（US）。
铊-201、MRI和五价DMSA对选定的疑似复发性不摄取碘甲状腺癌患者的随访具有足够的敏感性。
